## **BAZA HIGH CONVICTION FUND** QUARTER ENDED 31 MARCH 2021



+8.4% Absolute quarterly performance<sup>1</sup> +5.3% Relative outperformance vs. S&P/ASX 200 index during quarter<sup>2</sup> **A\$1.637** Unit price, 31-Mar-21<sup>2</sup> **+67.3%** Performance since inception (Jan-20)<sup>2</sup>

### **KEY METRICS FOR MARCH QUARTER 2021**

BHC unit price (pre fees and distribution)	A\$1.661
Performance fees for quarter	(A\$0.024)
Unit price post fees, pre distribution	A\$1.637
Distribution this quarter	-
Unit price post distribution and fees	A\$1.637
BHC performance in quarter (post fees)	+8.4%
S&P/ASX 200 (Benchmark) performance	+3.1%
Outperformance of BHC in quarter	+5.3%
BHC cumulative return since inception <sup>1</sup>	+67.3%

#### **FUND SNAPSHOT**


15 January 2020
Unit trust
Nil
22.5% (excl. GST) above Benchmark
S&P/ASX 200

#### Top 5 portfolio holdings (as at 31 March 2021):

New World Resources (ASX: NWC)	6.3%
Genex Power (ASX: GNX)	5.7%
Frontier Digital Ventures (ASX: FDV)	5.1%
Rhipe (ASX: RHP)	4.4%
Vital Metals (ASX: VML)	4.0%

1 Post fees and expenses 2 Includes A\$0.023 distribution declared 30 June 2020

### HISTORICAL PERFORMANCE CHART



### **PORTFOLIO WEIGHTING**



## BAZA HIGH CONVICTION FUND QUARTER ENDED 31 MARCH 2021

#### COMMENTARY

# The Fund returned 8.4% for the quarter, outperforming the Benchmark by 5.3%

Baza High Conviction (the **Fund**) delivered an increase in unit price of 8.4% to finish at A\$1.637 post fees and expenses. This compares to the S&P/ASX 200 index (**Benchmark**) which increased by 3.1% over the same period, an outperformance by the Fund of 5.3%. Since inception in January 2020, the Fund has delivered total returns of 67.3% post fees and expenses.

Summary of the key contributors and detractors for the March quarter:

#### Top 3 contributors for March quarter

Venturex Resources (ASX: VXR)	+2.8%
Pentanet Limited (ASX: 5GG)	+2.2%
Vital Metals	+1.9%
Top 3 detractors for March quarter	
New Century Resources (ASX: NCZ)	(1.2%)
Calidus Resources (ASX: CAI)	(1.0%)
Frontier Digital Ventures	(0.8%)

# Equity markets were relatively steady, despite significant newsflow over the quarter

The S&P/ASX 200 picked up where it left off in Dec-20 with the re-opening thematic catching fire. The local market peaked in mid-February, up +5.3%, before trailing off post results season to finish +3.1% for the quarter. Global equity markets recorded similar results, with the Dow Jones up 0.7% and the FTSE 100 up 3.9% for the quarter. Equity markets were buffeted by US stimulus announcements, vaccine roll-out issues, strong corporate results season and a gyrating bond market during the quarter. The muted response of share prices to strong earnings results may reflect that a large degree of the post-COVID reopening economic recovery is already priced into the market. This indicates heightened downside risks if COVID reopening hiccups persist (such as the slow roll-out of the vaccine and further lockdowns).

#### Gold equities were the key headwind for the quarter

The key drag on performance this quarter was our overweight position in gold equities (20.9% of FUM at 31-Dec-20).

The aggregate performance of gold equities reduced unit pricing by 3.1% over the quarter as gold prices collapsed from ~US\$1,950/oz to ~\$1,700/oz at quarter end, driven largely by the expectation of higher US real interest rates. Some pre-emptive selling of gold equities in January mitigated the impact to the Fund, and the overall gold exposure at 31-Mar-21 reduced to 9.3%.

#### Positioning for reflation starting to pay off...

The Fund's investments in base metal developers was a key driver of performance for the quarter. Our selection of copper developers continued to outperform; New World Resources (+34%), Eagle Metals (ASX: EM2) (+36%) and Caravel Minerals (ASX: CVV) (+8%) performed well over the quarter. The Fund held unlisted options in another base metals developer, Venturex, which undertook a transformative capital raising and introduced former Northern Star CEO, Bill Beament, to the Board. This resulted in a share price gain of +208% over the quarter, and the Fund was able to monetise its unlisted options at a significant profit.

# ...but the fund remains relatively liquid and nimble in the face of vaccine roll-out headaches

We remain concerned that the approved COVID-19 vaccines will not be rolled out fast enough to generate herd immunity. We maintain a database of vaccine roll-out rates announced by governments and the early signs are that key nations (USA, UK, mainland Europe) are lagging the rates required to fully immunise (2 jabs) 70-80% of its population by the end of 2021. If annual dosages are required, we may be faced with the possibility that COVID-19 will not be controlled and suppressed economic activity will persist. This could trigger a correction in equity markets and heighten the need for ongoing stimulus, hence the Fund maintains a balanced exposure to gold and companies with high liquidity in order to manage positions quickly if required.

For further information please contact:

William Sandover Chief Investment Officer ws@baza.capital +61 499 776 998

Brayden McCormack Chief Strategy Officer bm@baza.capital +61 401 025 296